Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings
暂无分享,去创建一个
S. Holmstrom | Erin L. Tomaszewski | Pierre Moise | Robert N. Krupnick | Jared Downing | Margaret Meyer | Shevani Naidoo | Stefan Holmstrom | R. Krupnick | E. Tomaszewski | M. Meyer | S. Naidoo | P. Moise | J. Downing | E. L. Tomaszewski
[1] Perspectives on treatment of metastatic castration-resistant prostate cancer. , 2013, The oncologist.
[2] F. Saad,et al. Current management of castrate-resistant prostate cancer. , 2010, Current oncology.
[3] D. Wood,et al. Stratification of postprostatectomy urinary function using expanded prostate cancer index composite. , 2013, Urology.
[4] F. Saad,et al. PROSPER: A phase 3 study of enzalutamide in nonmetastatic (M0) castration-resistant prostate cancer (CRPC) patients. , 2014 .
[5] J. Stanford,et al. Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. , 2002, Journal of the National Cancer Institute.
[6] O. Sartor,et al. Health-related quality of life in advanced prostate cancer and its treatments: biochemical failure and metastatic disease populations. , 2015, Clinical genitourinary cancer.
[7] B. Bokhour,et al. Sexuality after treatment for early prostate cancer: exploring the meanings of "erectile dysfunction". , 2001, Journal of general internal medicine.
[8] P. Scardino,et al. A measure of health-related quality of life among patients with localized prostate cancer: results from ongoing scale development. , 2005, Clinical prostate cancer.
[9] S. Fosså,et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. , 2008, European journal of cancer.
[10] R. Greil,et al. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. Sonn,et al. Differing perceptions of quality of life in patients with prostate cancer and their doctors. , 2009, The Journal of urology.
[12] N. Leidy,et al. Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[13] H. Payne,et al. Symptoms and health-related quality of life in castration-resistant prostate cancer: the patient's perspective , 2012 .
[14] B. Reeve,et al. International Society for Quality of Life Research commentary on the draft European Medicines Agency reflection paper on the use of patient-reported outcome (PRO) measures in oncology studies , 2016, Quality of Life Research.
[15] S. Daneshmand,et al. Patient Related Outcome Measures Dovepress Androgen Deprivation Therapy for Prostate Cancer: Long-term Safety and Patient Outcomes , 2022 .
[16] K. Pienta,et al. Measuring quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. , 1997, Urology.
[17] J. Cappelleri,et al. Patient-reported outcomes: conceptual issues. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[18] E. Antonarakis,et al. Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort , 2016, European urology.
[19] B. Tombal,et al. Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] D. Eton,et al. Prostate cancer and health‐related quality of life: a review of the literature , 2002, Psycho-oncology.
[21] I. Kim,et al. Nonmetastatic Castration-Resistant Prostate Cancer , 2014, Korean journal of urology.
[22] J. Beaumont,et al. Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. , 2010, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[23] Pennifer Erickson,et al. Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[24] A. Katz. What happened?: Sexual consequences of prostate cancer and its treatment , 2005 .
[25] C. Morris,et al. A STRUCTURED REVIEW OF PATIENT-REPORTED OUTCOME MEASURES (PROMs) FOR PROSTATE CANCER , 2009 .
[26] Elizabeth Molsen,et al. Content validity--establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2--assessing respondent understanding. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[27] D. Lubeck,et al. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database. , 1998, The Journal of urology.
[28] David Cella,et al. Brief assessment of priority symptoms in hormone refractory prostate cancer: The FACT Advanced Prostate Symptom Index (FAPSI) , 2003, Health and quality of life outcomes.
[29] M. Fishman,et al. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer , 2007, Quality of Life Research.
[30] John T. Wei,et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Hans T. Chung,et al. Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer. , 2011, International journal of radiation oncology, biology, physics.
[32] Y. Loriot,et al. ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer , 2015, Expert review of anticancer therapy.
[33] S. Goldenberg,et al. Patient preference and the impact of decision-making aids on prostate cancer treatment choices and post-intervention regret. , 2012, Current oncology.
[34] R. A. Robinson,et al. Patients' perceptions of quality of life after treatment for early prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] W. Linden,et al. Measuring symptoms in localized prostate cancer: a systematic review of assessment instruments , 2013, Prostate Cancer and Prostatic Diseases.
[36] John T. Wei,et al. Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. , 2011, The Journal of urology.